Protagonist Therapeutics, Inc.
Financials
Valuation Metrics
Protagonist Therapeutics, Inc.'s Market Cap is $8.51B. At end of 2025 it was $5.55B. Ranked #1010 of 3,111 in US market (top 32%), #325 of 1,445 on NASDAQ (top 22%), #51 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $8.51B | US#1,010/3,111 Sec#51/269 |
| Revenue | $74M | US#2,837/3,111 Sec#140/269 |
| Net Income | $-115M | US—/3,111 Sec—/269 |
| Total Assets | $697M | US#2,614/3,111 Sec#128/269 |
| Net Assets | $655M | US#2,068/3,111 Sec#85/269 |
| Employees | 132 | US#1,429/3,111 Sec#57/269 |
| Value | ||
| P/B | 12.98x | US#2,714/3,111 Sec#216/269 |
| P/S | 114.86x | US#2,919/3,111 Sec#184/269 |
| FCF Yield | -1.37% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -17.50% | US#2,503/3,111 Sec#99/269 |
| ROA | -16.45% | US#2,745/3,111 Sec#117/269 |
| Op. Margin | -192.36% | US#2,861/3,111 Sec#135/269 |
| Revenue Growth | 99.03% | US#147/3,111 Sec#33/269 |
| Earnings Growth | -147.29% | US#2,163/3,111 Sec#74/269 |
| Financial Health | ||
| Debt Ratio | 6.41% | US#65/3,111 Sec#31/269 |
| Total Debt | $10M | US#2,816/3,111 Sec#202/269 |
| FCF | $-116M | US#2,619/3,111 Sec#162/269 |
| Cash | $194M | US#1,758/3,111 Sec#120/269 |
| Current Ratio | 17.76x | US#140/3,111 Sec#43/269 |
| Performance | ||
| 1Y Return | 145.74% | US#143/3,111 Sec#50/269 |
| 1M Return | 0.50% | US#534/3,111 Sec#31/269 |
| From 52W High | -7.68% | US#473/3,111 Sec#22/269 |
| 1Y MDD | -16.38% | US#408/3,111 Sec#13/269 |
| Trading | ||
| Volume | 437,157 shares | US#1,957/3,111 Sec#194/269 |
| Trading Value | $58M | US#1,077/3,111 Sec#63/269 |
| Per Share | ||
| EPS | $-2.05 | US—/3,111 Sec—/269 |
| BPS | $9.67 | US#1,814/3,111 Sec#66/269 |
Company Info
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.